Results for: Systemic Lupus Erythematosus

HC Wainwright has initiated coverage on Alumis Inc. (ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, with a Buy rating and a $30 price target. The firm is bullish on Alumis’ lead drug candidate, ESK-001, a TYK2 inhibitor currently in Phase 3 trials for psoriasis and Phase 2 trials for systemic lupus erythematosus. HC Wainwright believes ESK-001 possesses superior efficacy and selectivity compared to existing TYK2 inhibitors like Sotyktu (deucravacitinib), potentially capturing a significant market share.

UCB and Biogen have announced positive results from their Phase 3 PHOENYCS GO study, showing that dapirolizumab pegol, combined with standard care, significantly improved disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE) after 48 weeks compared to placebo. This finding offers potential hope for a new treatment option for SLE, a debilitating autoimmune disease.